Roche to refloat Genentech for $2 billion:
This article was originally published in Clinica
Executive Summary
Roche estimates that it will raise more than $2 billion by refloating a minority of Genentech. The Swiss pharmaceutical company bought a majority of biotechnology company Genentech in 1990 and in June paid a further $4.2 billion for the remainder of the company, with the proviso that it would refloat up to 19%.